AGP Executive Report
Last update: 6 hours agoBiotech & Pharma Deals: GSK is buying Nuvalent for $10.6B to expand its targeted lung cancer pipeline, a major oncology bet for its new CEO. Clinical Innovation: Life Biosciences dosed the first patient in its Phase 1 ER‑100 epigenetic restoration trial for optic neuropathies, while Treos Bio shared long-term MSS metastatic colorectal cancer results tied to its PEPI platform. Public Health & Vaccines: UMD researchers reported early trial safety for a dual Lassa fever/rabies vaccine, and new Ebola vaccine work continues to push toward broader protection. Medical Tech Markets: Reports project smart medical devices hitting $132.1B by 2031 and medical device affairs outsourcing reaching $8.1B by 2031, reflecting growing regulatory and connected-care demand. Preclinical Testing Shift: ADME toxicology testing is forecast to nearly double to $17.48B by 2035 as regulators lean on in vitro and in silico methods. AI in Biomed: A collaboration aims to build an AI-enabled multi-omics platform for NF1 patient stratification and biomarker discovery. Tech & Industry: KBR won a $95M digital engineering contract for the US Space Force, and Helionis Labs raised pre-seed funding to tackle thermal management for high-power electronics.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
